Dennis Polk - Jan 3, 2022 Form 4 Insider Report for TD SYNNEX CORP (SNX)

Role
Executive Chair, Director
Signature
/s/ Simon Y. Leung, Attorney-in-Fact
Stock symbol
SNX
Transactions as of
Jan 3, 2022
Transactions value $
-$148,338
Form type
4
Date filed
1/5/2022, 02:24 PM
Previous filing
Dec 3, 2021
Next filing
Jan 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNX Common Stock Sale -$11K -96 -0.07% $114.32 142K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$457 -4 0% $114.31 142K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$12.6K -110 -0.08% $114.27 142K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$6.86K -60 -0.04% $114.26 142K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $114.24 142K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $114.21 142K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$3.43K -30 -0.02% $114.18 142K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $114.16 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.2K -98 -0.07% $114.15 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$228 -2 0% $114.14 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $114.09 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $114.02 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $113.98 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$456 -4 0% $113.96 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$10.9K -96 -0.07% $113.94 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $113.92 141K Jan 3, 2022 Direct F1
transaction SNX Common Stock Sale -$11.4K -100 -0.07% $113.85 141K Jan 3, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These sales were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 22,2021.